Otitis media in severe asthma associated with chronic rhinosinusitis with nasal polyps: a new therapeutic target for biologics

References

• Daval M, Picard H, Bequignon E, Bedbeder P, Coste A, Ayache D, Escabasse V. Chronic otitis media with effusion in chronic sinusitis with polyps. Ear Nose Throat J. 2018;97(8):E13–E18. doi:10.1177/014556131809700803.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Torretta S, Marseglia GL, Licari A, Chiappini E, Benazzo M, Tosca MA, Marchisio P. Allergy and otitis media in clinical practice. Curr Allergy Asthma Rep. 2020;20(8):33 doi:10.1007/s11882-020-00930-8.
   PubMed Web of Science ®Google Scholar
• Parietti-Winkler C, Baumann C, Gallet P, Gauchard G, Jankowski R. Otitis media with effusion as a marker of the inflammatory process associated to nasal polyposis. Rhinology. 2009;47(4):396–399. doi:10.4193/Rhin08.220.
   PubMed Web of Science ®Google Scholar
• Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx. 2011;38(4):456–461. doi:10.1016/j.anl.2010.11.016.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725–739. doi:10.1016/j.jaci.2020.01.020.
   PubMed Web of Science ®Google Scholar
• Kagoshima H, Hori R, Kojima T, Okanoue Y, Taguchi A, Yamamoto H, Hasebe K, Shoji K. Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: a case report. Respir Med Case Rep. 2020;30:101135. doi:10.1016/j.rmcr.2020.101135.
   PubMed Web of Science ®Google Scholar
• van der Lans RJL, van Spronsen E, Fokkens WJ, Reitsma S. Complete remission of severe eosinophilic otitis media with dupilumab: a case report. Laryngoscope. 2021;131(12):2649–2651. doi:10.1002/lary.29730.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi:10.1016/j.jaci.2020.05.032.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi:10.1016/S0140-6736(19)31881-1.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2021;S0091-6749(21):01459.
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reltsma S, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps. Rhinology. 2020;29:1–464.
   Google Scholar
• Numata T, Miyagawa H, Nishioka S, Okuda K, Utsumi H, Hashimoto M, Minagawa S, Ishikawa T, Hara H, Araya J, et al. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study. BMC Pulm Med. 2020;20(1):207. doi:10.1186/s12890-020-01248-x.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh K-M, Ramos S, Canonica GW, Hedgecock S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi:10.1111/j.1398-9995.2004.00772.x.
   PubMed Web of Science ®Google Scholar
• Dupin C, Belhadi D, Guilleminault L, Gamez A‐S, Berger P, De Blay F, Bonniaud P, Leroyer C, Mahay G, Girodet P‐O, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. doi:10.1111/cea.13614.
   PubMed Web of Science ®Google Scholar
• Iino Y, Takahashi E, Ida S, Kikuchi S. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media. Auris Nasus Larynx. 2019;46(2):196–203. doi:10.1016/j.anl.2018.07.011.
   PubMed Web of Science ®Google Scholar
• Eger K, Kroes JA, Ten Brinke A, Bel EH. Long-term therapy response to anti-IL-5 biologics in severe asthma-a real-life evaluation. J Allergy Clin Immunol Pract. 2021;9(3):1194–1200. doi:10.1016/j.jaip.2020.10.010.
   PubMed Web of Science ®Google Scholar
• Parietti-Winkler C, Jankowski R. Is there an association between otitis media and nasal polyposis? Curr Allergy Asthma Rep. 2011;11(6):521–525. doi:10.1007/s11882-011-0229-0.
   PubMed Web of Science ®Google Scholar
• Seo Y, Nonaka M, Pawankar R. Eosinophilic otitis media and comorbid asthma. Curr Opin Allergy Clin Immunol. 2020;20(1):9–13. doi:10.1097/ACI.0000000000000589.
   PubMed Web of Science ®Google Scholar
• Hamada S, Ogino E, Yasuba H. Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media. Allergol Int. 2021;70(3):389–391. doi:10.1016/j.alit.2021.02.002.
   Web of Science ®Google Scholar
• Chow K, Cosetti MK. Use of IL-5 inhibitor benralizumab as a novel therapy for eosinophilic otitis media: clinical capsule and review of literature. Otol Neurotol. 2020;41(2):e238–e240. doi:10.1097/MAO.0000000000002493.
   PubMed Web of Science ®Google Scholar
• Passali D, Passali GC, Lauriello M, Romano A, Bellussi L, Passali FM. Nasal allergy and otitis media: a real correlation? Sultan Qaboos Univ Med J. 2014;14(1):e59-64–64. doi:10.12816/0003337.
   PubMedGoogle Scholar
• Kanazawa H, Yoshida N, Yamamoto H, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Iino Y. Risk factors associated with severity of eosinophilic otitis media. Auris Nasus Larynx. 2014;41(6):513–517. doi:10.1016/j.anl.2014.08.003.
   PubMed Web of Science ®Google Scholar
• Ohta N, Ishida A, Kurakami K, Suzuki Y, Kakehata S, Ono J, Ikeda H, Okubo K, Izuhara K. Expressions and roles of periostin in otolaryngological diseases. Allergol Int. 2014;63(2):171–180. doi:10.2332/allergolint.13-RAI-0673.
   PubMed Web of Science ®Google Scholar
• Miura T, Matsubara A, Kudo N, Hara R, Takahata J, Sasaki A. The expression of thymic stromal lymphopoietin in patients and animal models with eosinophilic otitis media. Acta Otolaryngol. 2018;138(5):447–451. doi:10.1080/00016489.2017.1416170.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Turk F, Leighton T, Canonica GW. Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ. 2007;10(3):285–296. doi:10.3111/13696990701478856.
   Google Scholar